Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166

1.

Prevalence and determinants for malnutrition in geriatric outpatients.

van Bokhorst-de van der Schueren MA, Lonterman-Monasch S, de Vries OJ, Danner SA, Kramer MH, Muller M.

Clin Nutr. 2013 Dec;32(6):1007-11. doi: 10.1016/j.clnu.2013.05.007. Epub 2013 May 17.

PMID:
23755842
2.

Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA.

Feeney ER, van Vonderen MG, Wit F, Danner SA, van Agtmael MA, Villarroya F, Domingo P, Capeau J, Reiss P, Mallon PW; MEDICLAS, NECATT study groups.

AIDS. 2012 Nov 13;26(17):2165-74. doi: 10.1097/QAD.0b013e328358b279.

PMID:
22874517
3.

The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentration.

Bierman WF, van Vonderen MG, Veldkamp AI, Burger DM, Danner SA, Reiss P, van Agtmael MA.

Antivir Ther. 2011;16(5):647-55. doi: 10.3851/IMP1824.

PMID:
21817186
4.

Multifactorial intervention to reduce falls in older people at high risk of recurrent falls: a randomized controlled trial.

de Vries OJ, Peeters GM, Elders PJ, Muller M, Knol DL, Danner SA, Bouter LM, Lips P.

Arch Intern Med. 2010 Jul 12;170(13):1110-7. doi: 10.1001/archinternmed.2010.169.

PMID:
20625015
5.

Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines.

Bierman WF, Scheffer GL, Schoonderwoerd A, Jansen G, van Agtmael MA, Danner SA, Scheper RJ.

J Antimicrob Chemother. 2010 Aug;65(8):1672-80. doi: 10.1093/jac/dkq209. Epub 2010 Jun 15.

PMID:
20551216
6.

Insulin sensitivity in multiple pathways is differently affected during zidovudine/lamivudine-containing compared with NRTI-sparing combination antiretroviral therapy.

van Vonderen MG, Blümer RM, Hassink EA, Sutinen J, Ackermans MT, van Agtmael MA, Yki-Jarvinen H, Danner SA, Serlie MJ, Sauerwein HP, Reiss P.

J Acquir Immune Defic Syndr. 2010 Feb;53(2):186-93. doi: 10.1097/QAI.0b013e3181c190f4.

PMID:
19898246
7.

Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss.

van Vonderen MG, van Agtmael MA, Hassink EA, Milinkovic A, Brinkman K, Geerlings SE, Ristola M, van Eeden A, Danner SA, Reiss P; MEDICLAS study group.

PLoS One. 2009 May 21;4(5):e5647. doi: 10.1371/journal.pone.0005647.

8.

First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.

van Vonderen MG, Lips P, van Agtmael MA, Hassink EA, Brinkman K, Geerlings SE, Sutinen J, Ristola M, Danner SA, Reiss P.

AIDS. 2009 Jul 17;23(11):1367-76. doi: 10.1097/QAD.0b013e32832c4947.

PMID:
19424051
9.

Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy.

van Vonderen MG, Hassink EA, van Agtmael MA, Stehouwer CD, Danner SA, Reiss P, Smulders Y.

J Infect Dis. 2009 Apr 15;199(8):1186-94. doi: 10.1086/597475.

PMID:
19275490
10.

A context-learning pharmacotherapy program for preclinical medical students leads to more rational drug prescribing during their clinical clerkship in internal medicine.

Richir MC, Tichelaar J, Stanm F, Thijs A, Danner SA, Schneider AJ, de Vries TP.

Clin Pharmacol Ther. 2008 Oct;84(4):513-6.

PMID:
19238657
11.

Carotid intima-media thickness and arterial stiffness in HIV-infected patients: the role of HIV, antiretroviral therapy, and lipodystrophy.

van Vonderen MG, Smulders YM, Stehouwer CD, Danner SA, Gundy CM, Vos F, Reiss P, Agtmael MA.

J Acquir Immune Defic Syndr. 2009 Feb 1;50(2):153-61. doi: 10.1097/QAI.0b013e31819367cd.

PMID:
19131894
12.

HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.

Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA.

AIDS. 2009 Jan 28;23(3):279-91. doi: 10.1097/QAD.0b013e32831c54e5. Review.

PMID:
19114854
13.

Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.

Blümer RM, van Vonderen MG, Sutinen J, Hassink E, Ackermans M, van Agtmael MA, Yki-Jarvinen H, Danner SA, Reiss P, Sauerwein HP.

AIDS. 2008 Jan 11;22(2):227-36.

PMID:
18097225
14.

Quantitative detection of Staphylococcus aureus and Enterococcus faecalis DNA in blood to diagnose bacteremia in patients in the intensive care unit.

Peters RP, van Agtmael MA, Gierveld S, Danner SA, Groeneveld AB, Vandenbroucke-Grauls CM, Savelkoul PH.

J Clin Microbiol. 2007 Nov;45(11):3641-6. Epub 2007 Sep 19.

15.

Rapid identification of pathogens in blood cultures with a modified fluorescence in situ hybridization assay.

Peters RP, van Agtmael MA, Simoons-Smit AM, Danner SA, Vandenbroucke-Grauls CM, Savelkoul PH.

J Clin Microbiol. 2006 Nov;44(11):4186-8.

16.

Cutting edge: Rapid recovery of NKT cells upon institution of highly active antiretroviral therapy for HIV-1 infection.

van der Vliet HJ, van Vonderen MG, Molling JW, Bontkes HJ, Reijm M, Reiss P, van Agtmael MA, Danner SA, van den Eertwegh AJ, von Blomberg BM, Scheper RJ.

J Immunol. 2006 Nov 1;177(9):5775-8.

17.

Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.

Kwong GP, Ghani AC, Rode RA, Bartley LM, Cowling BJ, da Silva B, Donnelly CA, van Sighem AI, Cameron DW, Danner SA, de Wolf F, Anderson RM.

AIDS. 2006 Oct 3;20(15):1941-50.

PMID:
16988515
18.

Effects of nandrolone decanoate compared with placebo or testosterone on HIV-associated wasting.

Gold J, Batterham MJ, Rekers H, Harms MK, Geurts TB, Helmyr PM, Silva de Mendonça J, Falleiros Carvalho LH, Panos G, Pinchera A, Aiuti F, Lee C, Horban A, Gatell J, Phanuphak P, Prasithsirikul W, Gazzard B, Bloch M, Danner SA; E-1696 Study Investigators.

HIV Med. 2006 Apr;7(3):146-55.

19.

Faster identification of pathogens in positive blood cultures by fluorescence in situ hybridization in routine practice.

Peters RP, Savelkoul PH, Simoons-Smit AM, Danner SA, Vandenbroucke-Grauls CM, van Agtmael MA.

J Clin Microbiol. 2006 Jan;44(1):119-23.

20.

Macronodular adrenocortical hyperplasia in a postmenopausal woman.

Mijnhout GS, Danner SA, van de Goot FR, van Dam EW.

Neth J Med. 2004 Dec;62(11):454-5.

21.

New developments in the diagnosis of bloodstream infections.

Peters RP, van Agtmael MA, Danner SA, Savelkoul PH, Vandenbroucke-Grauls CM.

Lancet Infect Dis. 2004 Dec;4(12):751-60. Review.

PMID:
15567125
22.

Detection of bacterial DNA in blood samples from febrile patients: underestimated infection or emerging contamination?

Peters RP, Mohammadi T, Vandenbroucke-Grauls CM, Danner SA, van Agtmael MA, Savelkoul PH.

FEMS Immunol Med Microbiol. 2004 Oct 1;42(2):249-53.

23.

TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen.

Sankatsing SU, Weverling GJ, Peeters M, van't Klooster G, Gruzdev B, Rakhmanova A, Danner SA, Jurriaans S, Prins JM, Lange JM.

AIDS. 2003 Dec 5;17(18):2623-7.

PMID:
14685056
24.

Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients.

van der Ende ME, Prins JM, Brinkman K, Keuter M, Veenstra J, Danner SA, Niesters HG, Osterhaus AD, Schutten M.

AIDS. 2003 Jul;17 Suppl 3:S55-61.

PMID:
14565610
25.

QUOTE-HIV: an instrument for assessing quality of HIV care from the patients' perspective.

Hekkink CF, Sixma HJ, Wigersma L, Yzermans CJ, Van Der Meer JT, Bindels PJ, Brinkman K, Danner SA.

Qual Saf Health Care. 2003 Jun;12(3):188-93.

26.

Post-exposure prophylaxis.

van der Ende ME, Regez RM, Schreij G, van der Meer JT, Danner SA; Dutch PEP registration.

Int J STD AIDS. 2002 Dec;13 Suppl 2:30-4.

PMID:
12537723
27.

Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection.

Nieuwkerk PT, Gisolf EH, Reijers MH, Lange JM, Danner SA, Sprangers MA; NATIVE Study Group; PROMETHEUS Study Group; ADAM Study Group.

AIDS. 2001 Oct 19;15(15):1985-91.

PMID:
11600827
28.

Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.

Nieuwkerk PT, Sprangers MA, Burger DM, Hoetelmans RM, Hugen PW, Danner SA, van Der Ende ME, Schneider MM, Schrey G, Meenhorst PL, Sprenger HG, Kauffmann RH, Jambroes M, Chesney MA, de Wolf F, Lange JM; ATHENA Project.

Arch Intern Med. 2001 Sep 10;161(16):1962-8.

PMID:
11525698
29.

[HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].

Jambroes M, Weverling GJ, Reiss P, Danner SA, Jurriaans S, ten Veen JH, van der Ende ME, Schutten M, Schneider MM, Schuurman R, Mulder JW, Kroes AC, Lange JM, de Wolf F; Kliniek en Virologie van het ATHENA-project.

Ned Tijdschr Geneeskd. 2001 Aug 18;145(33):1591-7. Dutch.

PMID:
11534377
30.

[CBO guidelines 'Antiretroviral therapy in the Netherlands'].

Borleffs JC, Danner SA, Lange JM, van Everdingen JJ; Commissie Richtlijnen van de Nederlandse Vereniging van Aids Behandelaren.

Ned Tijdschr Geneeskd. 2001 Aug 18;145(33):1585-9. Review. Dutch.

PMID:
11534375
31.

A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience.

Schooley RT, Clumeck N, Haubrich R, Thompson M, Danner SA, van Der Ende ME, Sereni D, Antunes F, Blake D, Myers RE, Tisdale M, Millard J, Mustafa N, Nacci P.

Antivir Ther. 2001 Jun;6(2):89-96.

PMID:
11491421
32.

Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses.

Notermans DW, de Jong JJ, Goudsmit J, Bakker M, Roos MT, Nijholt L, Cremers J, Hellings JA, Danner SA, de Ronde A.

AIDS Res Hum Retroviruses. 2001 Jul 20;17(11):1003-8.

PMID:
11485617
33.

Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs.

Lukashov VV, Huismans R, Jebbink MF, Danner SA, de Boer RJ, Goudsmit J.

AIDS Res Hum Retroviruses. 2001 Jun 10;17(9):807-18.

PMID:
11429122
34.

T cell expansions in lymph nodes and peripheral blood in HIV-1-infected individuals: effect of antiretroviral therapy.

Kostense S, Raaphorst FM, Joling J, Notermans DW, Prins JM, Danner SA, Reiss P, Lange JM, Teale JM, Miedema F.

AIDS. 2001 Jun 15;15(9):1097-107.

PMID:
11416711
35.

Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.

van der Valk M, Gisolf EH, Reiss P, Wit FW, Japour A, Weverling GJ, Danner SA; Prometheus study group.

AIDS. 2001 May 4;15(7):847-55.

PMID:
11399957
36.

No beneficial effect of interferon-gamma treatment in 2 human immunodeficiency virus-infected patients with Mycobacterium avium complex infection.

Lauw FN, van Der Meer JT, de Metz J, Danner SA, van Der Poll T.

Clin Infect Dis. 2001 Feb 15;32(4):e81-2. Epub 2001 Feb 7.

PMID:
11181141
37.

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.

den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, Pakker NG, Reiss P, Danner SA, Weverling GJ, Lange JM.

AIDS. 2000 Dec 22;14(18):2895-902.

PMID:
11153671
38.

Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy.

Gisolf EH, van Praag RM, Jurriaans S, Portegies P, Goudsmit J, Danner SA, Lange JM, Prins JM.

J Acquir Immune Defic Syndr. 2000 Dec 15;25(5):426-33.

PMID:
11141242
39.

Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group.

Gisolf EH, Dreezen C, Danner SA, Weel JL, Weverling GJ; Prometheus Study Group.

Clin Infect Dis. 2000 Nov;31(5):1234-9. Epub 2000 Nov 6.

PMID:
11073757
40.

Evaluation of a second-generation nucleic acid sequence-based amplification assay for quantification of HIV type 1 RNA and the use of ultrasensitive protocol adaptations.

Notermans DW, de Wolf F, Oudshoorn P, Cuijpers HT, Pirillo M, Tiller FW, McClernon DR, Prins JM, Lange JM, Danner SA, Goudsmit J, Jurriaans S.

AIDS Res Hum Retroviruses. 2000 Oct 10;16(15):1507-17.

PMID:
11054264
41.

Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases.

ter Hofstede HJ, de Marie S, Foudraine NA, Danner SA, Brinkman K.

Int J STD AIDS. 2000 Sep;11(9):611-6.

PMID:
10997508
42.

Influence of follicular dendritic cells on decay of HIV during antiretroviral therapy.

Hlavacek WS, Stilianakis NI, Notermans DW, Danner SA, Perelson AS.

Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10966-71.

43.

Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine.

Gisolf EH, Enting RH, Jurriaans S, de Wolf F, van der Ende ME, Hoetelmans RM, Portegies P, Danner SA.

AIDS. 2000 Jul 28;14(11):1583-9.

PMID:
10983645
44.

T-cell progenitor function during progressive human immunodeficiency virus-1 infection and after antiretroviral therapy.

Clark DR, Repping S, Pakker NG, Prins JM, Notermans DW, Wit FW, Reiss P, Danner SA, Coutinho RA, Lange JM, Miedema F.

Blood. 2000 Jul 1;96(1):242-9.

45.

The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.

van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FW, Lange JM, Danner SA, Foudraine NA, Kwakkelstein MO, Reiss P, Beijnen JH, Hoetelmans RM.

AIDS. 2000 May 26;14(8):F77-82.

PMID:
10853971
46.
47.

The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group.

Gisolf EH, Jurriaans S, Pelgrom J, van Wanzeele F, van der Ende ME, Brinkman K, Borst MJ, de Wolf F, Japour AJ, Danner SA.

AIDS. 2000 Mar 10;14(4):405-13.

PMID:
10770543
48.

Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy. The Prometheus Study Group.

Nieuwkerk PT, Gisolf EH, Colebunders R, Wu AW, Danner SA, Sprangers MA.

AIDS. 2000 Jan 28;14(2):181-7.

PMID:
10708289
49.

Antigen-driven CD4+ T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy.

Ferguson NM, deWolf F, Ghani AC, Fraser C, Donnelly CA, Reiss P, Lange JM, Danner SA, Garnett GP, Goudsmit J, Anderson RM.

Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15167-72.

50.

Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells.

Zhang Z, Schuler T, Zupancic M, Wietgrefe S, Staskus KA, Reimann KA, Reinhart TA, Rogan M, Cavert W, Miller CJ, Veazey RS, Notermans D, Little S, Danner SA, Richman DD, Havlir D, Wong J, Jordan HL, Schacker TW, Racz P, Tenner-Racz K, Letvin NL, Wolinsky S, Haase AT.

Science. 1999 Nov 12;286(5443):1353-7. Erratum in: Science 1999 Dec 17;286(5448):2273.

Supplemental Content

Loading ...
Support Center